Biological product filing citing a Science Translational Medicine paper — Atyr Pharma, 2025-03-13
Atyr PharmaAtyr PharmaNASDAQ ATYR
Filings SEC · Quote Yahoo cited a paper published in Science Translational Medicine in a regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was noted. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the unscheduled report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by Atyr Pharma on 2025-03-13 was 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Science Translational Medicine in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
Publication in Science Translational Medicine validates efzofitimod’s mechanism of action. Company to host conference call and webcast today, March 13th at 5:00 p.m.
What readers should look at first is where the company placed the paper in the press release. Next, they need to determine whether the paper supports the entire company's claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has read only the abstract, cannot provide an answer.
The scope of the paper mentioned in the abstract is limited to this.
The title of the paper is A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis and it was published in Science Translational Medicine on 2025-03-12. The authors' affiliations are aTyr Pharma (United States) · Hong Kong University of Science and Technology · Pantarei Design (China) · University of Hong Kong. The summary published at the beginning of the paper is called abstract. This article has read only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, so it is of a different grade from a full-text reading and a verified reading.
This research targets interstitial lung diseases that cause inflammation and fibrosis in the lungs, by developing a drug from a fragment of a human enzyme. Starting from the observation that a variant fragment cut from histidyl-tRNA synthetase is abundant in the lungs and increases in response to inflammatory signals, the study showed through cell experiments that this fragment binds to neuropilin-2 on the surface of immune cells and reduces inflammatory signals. In various animal models such as bleomycin-induced lung injury, pulmonary fibrosis, and sarcoidosis, inflammation, immune cell infiltration, and fibrosis were reduced. Patient results are in the latter part of the abstract. This article does not include that section.
What the abstract does not answer remains in the main text and appendix. This article leaves the blank as it is, without going further. Readers are to judge for themselves which sentence in the abstract corresponds to the cited excerpt from the company, by comparing the two citations above.
One month later, the stock price was in the bottom quarter of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. Dates are counted only on days when the stock market is open, referred to as trading days. In terms of the calendar, 20 trading days are approximately one month. The excess return on the day of the filing and for the following month are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +16.7% | The extent of movement before the filing |
| On the filing day | +13.9% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +4.2% | One week |
| Accumulated over +1 to +20 trading days | −27.1% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -27.1% in this case is within the bottom quarter, at the 17% position from the bottom among 142 cases in the sample.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −27.1% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
After the filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed with only item numbers. In 8-K filings without titles, item numbers indicate the type of content. One can determine whether it was an earnings announcement or a contract based on the item number. The specific event is described in the original text accessible via each link.
- 2025-05-06 8-K Items 5.02,5.07,9.01 — Officer and Director Changes · Shareholder Meeting Results · Financial Statements and Exhibits
- 2025-05-07 8-K Item 2.02, 9.01 — Earnings Announcement · Financial Statements · Attached Documents
- 2025-08-07 8-K Item 2.06, 9.01 — Financial Statements and Exhibits
What this article does not answer
This article, based only on abstracts, cannot answer what methods the papers used, what they reviewed, or how far they went. How many times the cited paper has been referenced afterward can be verified again using the citation count from OpenAlexOpenAlex
Data source · Website. What will be examined next is whether the company's subsequent 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement of the company alone by removing the part where the market as a whole rises or falls.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days are about a month in the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full paper, one cannot know the details and limitations of the methods.